StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock.
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The company's fifty day moving average is $0.09.
Get
LadRx alerts:
LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
Read More
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock.
StockNews.com 开始报道的股票 LadRx（纳斯达克股票代码：CYTR — 获取评级） 在周四发布的一份报告中。该经纪公司对该股发布了持有评级。
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The company's fifty day moving average is $0.09.
LadRx创下52周低点0.05美元，52周高点为0.86美元。该公司的五十天移动平均线为0.09美元。
Get
LadRx
alerts:
LadRx Company Profile
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LadRx Corp. 是一家生物制药研发公司，从事新型抗癌候选药物的发现、研究和临床开发。它专注于开发Linker Activated Drue Release（LADR）技术平台，该平台是一个发现引擎，可帮助创建抗癌分子管道，避免不可接受的全身毒性，同时将高效药物直接输送到肿瘤。
Read More
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
- 免费获取 StockNews.com 关于 LadrX (CYTR) 的研究报告
- MarketBeat 一周回顾 — 2/6 — 2/10
- Snowflake 会玩艰难的雪橇，想保持拉力赛活力吗？
- Cloudflare 股票已触底
- 引领模因股票复苏的 3 只股票
- 微软-动视暴雪合并：驾驭风险与回报
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 LadRx 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收LadrX及相关公司的最新新闻和分析师评级的简明每日摘要。
